This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.
September 2017 in “Journal of Investigative Dermatology” LRIG1 protein affects hair growth by regulating skin receptors, leading to hair loss when overexpressed.
December 2025 in “Biomedicines” This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.
January 2021 in “Journal of Cancer Therapy” This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.
58 citations
,
March 2020 in “Scientific Reports” This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.